(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 20.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Cue Biopharma's revenue in 2026 is $27,466,000.On average, 2 Wall Street analysts forecast CUE's revenue for 2026 to be $98,637,399, with the lowest CUE revenue forecast at $95,707,575, and the highest CUE revenue forecast at $102,543,831. On average, 2 Wall Street analysts forecast CUE's revenue for 2027 to be $98,637,399, with the lowest CUE revenue forecast at $95,707,575, and the highest CUE revenue forecast at $102,543,831.
In 2028, CUE is forecast to generate $5,370,855,201 in revenue, with the lowest revenue forecast at $95,707,575 and the highest revenue forecast at $11,064,967,620.